Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)

Clinical trial NCT07581314 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07581314
Sponsor: Telomir Pharmaceuticals, Inc.
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Triple-Negative Breast Cancer (TNBC)Advanced Triple-Negative Breast Cancer Metastatic Triple-negative Breast Cancer

Start date: 2026-10-01
Primary completion: 2027-05-01
Enrollment: 76

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.